Stephen K. Brannan, MD

  • 3Articles
  • 25.6KReads
  • 2005–2025Active
  • 22Collaborators
  • 63Citations

About

Stephen K. Brannan, MD is affiliated with Medical Affairs, Bristol Myers Squibb, Princeton, New Jersey. Stephen K. Brannan has authored or co-authored 3 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2005 and 2025. Their work focuses on Schizophrenia/Schizoaffective Disorders and Depression (MDD).

Publications

JCP
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
Original Research

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
, , , et al
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
, , , et al
JCP
Original Research

Sexual Functioning Assessed in 4 Double-Blind Placebo- and Paroxetine-Controlled Trials of Duloxetine for Major Depressive Disorder

June 15, 2005

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe